Loading...
Loading...
IONS| Name | Value |
|---|---|
| Revenues | 134.0M |
| Cost of Revenue | 1.1M |
| Gross Profit | 132.9M |
| Operating Expense | 281.4M |
| Operating I/L | -148.7M |
| Other Income/Expense | 4.6M |
| Interest Income | 2.2M |
| Pretax | -144.1M |
| Income Tax Expense | -4.0M |
| Net Income/Loss | -140.5M |
Ionis Pharmaceuticals, Inc. is a leading biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics. The company's revenue is primarily generated through the sale of its innovative medicines, including SPINRAZA for spinal muscular atrophy, TEGSEDI for hereditary transthyretin-mediated amyloidosis, and WAYLIVRA for familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also earns income from its strategic collaborations with industry giants such as Biogen Inc., AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. The company's pipeline includes promising treatments for various diseases, positioning it as a key player in the pharmaceutical industry.
